NEW
YORK, Feb. 29, 2024 /PRNewswire/ -- Hoth
Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused
biopharmaceutical company, today announced that it will
continue its work with Venable, LLP to develop and protect its
intellectual property. Venable is an American Lawyer Global
100 law firm that serves as primary counsel to a worldwide
clientele of large and mid-sized organizations and nonprofits and
individuals. With more than 900 professionals across the country,
the firm strategically advances its clients' objectives in
the United States and around the
globe. Venable advises clients on a broad range of topics,
including the full range of intellectual property disciplines.
Venable's nationally recognized intellectual property team
consistently delivers high-quality, practical analyses and advice
rooted in real-world experience. Venable is dedicated to helping
clients protect their intellectual property while providing
comprehensive advice on strategy, filing and prosecution,
licensing, and related enforcement matters.
"We believe this collaboration with Venable will greatly add
value and further protect our expanding research and development of
life-changing therapeutics," said Robb
Knie, chief executive officer.
"Our team is greatly looking forward to continuing our
partnership with Hoth Therapeutics in the next iteration of our
engagement," said Jason Okun, a
partner in Venable's Intellectual Property Division.
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical
company dedicated to developing innovative, impactful, and
ground-breaking treatments with a goal to improve patient quality
of life. We are a catalyst in early-stage pharmaceutical research
and development, elevating drugs from the bench to pre-clinical and
clinical testing. Utilizing a patient-centric approach, we
collaborate and partner with a team of scientists, clinicians, and
key opinion leaders to seek out and investigate therapeutics that
hold immense potential to create breakthroughs and diversify
treatment options. To learn more, please visit
https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes
forward-looking statements based upon Hoth's current expectations,
which may constitute forward-looking statements for the purposes of
the safe harbor provisions under the Private Securities Litigation
Reform Act of 1995 and other federal securities laws, and are
subject to substantial risks, uncertainties, and assumptions. These
statements concern Hoth's business strategies; the timing of
regulatory submissions; the ability to obtain and maintain
regulatory approval of existing product candidates and any other
product candidates we may develop, and the labeling under any
approval we may obtain; the timing and costs of clinical trials,
and the timing and costs of other expenses; market acceptance of
our products; the ultimate impact of the current coronavirus
pandemic, or any other health epidemic, on our business, our
clinical trials, our research programs, healthcare systems, or the
global economy as a whole; our intellectual property; our reliance
on third-party organizations; our competitive position; our
industry environment; our anticipated financial and operating
results, including anticipated sources of revenues; our assumptions
regarding the size of the available market, benefits of our
products, product pricing, and timing of product launches;
management's expectation with respect to future acquisitions;
statements regarding our goals, intentions, plans, and
expectations, including the introduction of new products and
markets; and our cash needs and financing plans. There are a number
of factors that could cause actual events to differ materially from
those indicated by such forward-looking statements. You should not
place reliance on these forward-looking statements, which include
words such as "could," "believe," "anticipate," "intend,"
"estimate," "expect," "may," "continue," "predict," "potential,"
"project" or similar terms, variations of such terms, or the
negative of those terms. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, the Company cannot guarantee such outcomes. Hoth may
not realize its expectations, and its beliefs may not prove
correct. Actual results may differ materially from those indicated
by these forward-looking statements as a result of various
important factors, including, without limitation, market conditions
and the factors described in the section titled "Risk Factors" in
Hoth's most recent Annual Report on Form 10-K and Hoth's other
filings made with the U. S. Securities and Exchange Commission. All
such statements speak only as of the date made. Consequently,
forward-looking statements should be regarded solely as Hoth's
current plans, estimates, and beliefs. Investors should not place
undue reliance on forward-looking statements. Hoth cannot guarantee
future results, events, levels of activity, performance, or
achievements. Hoth does not undertake and specifically declines any
obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events, or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download
multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-retains-venable-llp-to-expand-its-patent-portfolio-302074403.html
SOURCE Hoth Therapeutics, Inc.